Life sciences location decisions have never been more complex. Companies across the biotechnology, pharmaceutical, medical device and testing and diagnostics industries must balance access to scientific, engineering, commercial and manufacturing talent with increasingly demanding requirements for power, water, infrastructure and specialized facilities.
BLS & Co. helps companies navigate these tradeoffs and identify and qualify locations that can support increasingly complex operations while accelerating speed to market, managing risk and controlling costs. Drawing on decades of experience advising some of the world's leading life sciences companies, BLS brings together location strategy, labor market analysis, infrastructure and utility due diligence, incentives strategy and site development risk assessment to help clients make confident, long-term investment decisions.
BLS & Co. helps clients select locations for administrative, research, development and manufacturing facilities, as well as corporate headquarters, and works with companies to obtain economic development incentives. Our services include:
We are best known for the breadth and sophistication of our incentives advisory services and have been involved in transactions in almost every state. Through our international partners we are also able to serve clients elsewhere in North and South America as well as Europe and Asia.
BLS & Co. has advised global pharmaceutical leader Eli Lilly & Company (Lilly) on competitive site searches supporting 13 new global sites since 2020 accounting for more than $57 billion in announced investments in next-generation production facilities. Our engagements with Lilly date back more than two decades.
Since 2020, BLS has advised Lilly on the site selection and incentives negotiation for 10 new U.S. manufacturing and R&D sites, resulting in more than $50 billion in announced investment, 6,500 new positions and more than $2.9 billion in state and local incentives secured.
In Europe, BLS and our European partner firm, Location Decisions, have assisted Lilly with three recent manufacturing site selection requirements, resulting in more than $7.5 billion in investment and 2,000 announced jobs.
Across our relationship with Lilly, BLS has provided a full range of strategic location advisory services, including multi-state site selection, infrastructure due diligence, labor market analysis, incentives strategy & transaction management, utility & infrastructure evaluations, regulatory risk assessments, and incentives compliance support.
US Project Highlights
Europe Project Highlights

BLS & Co. served as site selection and incentives advisor to Bristol Myers Squibb dating back more than two decades. Our engagements include have included complex and highly competitive nationwide searches for both manufacturing and office projects which have resulted in over $3.3 billion in announced investment.
BLS & Co. served as site selection and incentives consultant for Bristol Myers Squibb’s new $2.3B multi-modal manufacturing facility in Houston, Texas. The project continued BLS & Co.'s decades-long relationship with BMS that has also involved substantial office and manufacturing projects in Florida and Massachusetts.
BLS & Co. serves as location and incentives advisor to Roche, Swiss multinational healthcare leader, and its subsidiary Genentech, the South San Francisco-based biotechnology industry leader. Our engagements with Roche date back to 2012, supporting over $2.7 billion in announced investments.
BLS & Co. serves aslocation and incentives advisor to Roche, Swiss multinational healthcarecompany, and its subsidiary Genentech, the South San Francisco-basedbiotechnology industry leader. Our engagements with Roche date back to 2012with four major projects announced as of 2026: